

Leonor Arenillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6308341/publications.pdf>

Version: 2024-02-01

79
papers

2,026
citations

361413
20
h-index

243625
44
g-index

79
all docs

79
docs citations

79
times ranked

3184
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011, 117, 4836-4843.	1.4	280
2	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	1.6	253
3	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 3005-3015.	1.4	251
4	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	3.5	196
5	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	3.5	100
6	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	3.5	81
7	Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. <i>Haematologica</i> , 2012, 97, 1036-1041.	3.5	79
8	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. <i>British Journal of Haematology</i> , 2013, 162, 74-86.	2.5	73
9	Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2008, 112, 640-640.	1.4	73
10	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. <i>Haematologica</i> , 2013, 98, 568-575.	3.5	63
11	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1167-1177.	2.8	44
12	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. <i>Clinical Cancer Research</i> , 2014, 20, 1007-1019.	7.0	44
13	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006, 76, 58-63.	2.2	36
14	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. <i>Haematologica</i> , 2008, 93, 1001-1008.	3.5	36
15	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	1.3	36
16	Response to thalidomide in multiple myeloma: impact of angiogenic factors. <i>Cytokine</i> , 2004, 26, 145-148.	3.2	34
17	Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. <i>Blood Advances</i> , 2020, 4, 5285-5296.	5.2	27
18	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2012, 159, 311-321.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. <i>Annals of Hematology</i> , 2014, 93, 1695-1703.	1.8	25
20	Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. <i>Leukemia Research</i> , 2010, 34, 1242-1245.	0.8	23
21	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.	1.6	20
22	The phenotypic spectrum of germline <i>YARS2</i> variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2. <i>Haematologica</i> , 2018, 103, 2008-2015.	3.5	19
23	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. <i>PLoS ONE</i> , 2015, 10, e0129375.	2.5	19
24	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 778-788.	3.5	17
25	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does <i>7/7q</i> detection by FISH have prognostic value?. <i>Leukemia Research</i> , 2013, 37, 416-421.	0.8	16
26	Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.. <i>Blood</i> , 2009, 114, 290-290.	1.4	14
27	Circulating cell-free DNA improves the molecular characterisation of Philadelphia-negative myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2021, 192, 300-309.	2.5	13
28	Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma. <i>Acta Haematologica</i> , 2006, 116, 203-206.	1.4	12
29	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS). <i>American Journal of Hematology</i> , 2017, 92, 614-621.	4.1	12
30	Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2008, 185, 32-36.	1.0	11
31	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. <i>Leukemia Research</i> , 2013, 37, 769-776.	0.8	11
32	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <i>Modern Pathology</i> , 2016, 29, 1541-1551.	5.5	11
33	Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution. <i>Leukemia and Lymphoma</i> , 2007, 48, 1968-1975.	1.3	10
34	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. <i>Haematologica</i> , 2010, 95, 1798-1800.	3.5	9
35	Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. <i>Blood Advances</i> , 2019, 3, 3579-3589.	5.2	7
36	Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. <i>EBioMedicine</i> , 2022, 80, 104059.	6.1	7

#	ARTICLE	IF	CITATIONS
37	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. <i>Blood Advances</i> , 2022, 6, 3921-3931.	5.2	7
38	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. <i>American Journal of Hematology</i> , 2017, 92, E534-E541.	4.1	6
39	Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. <i>Blood Advances</i> , 2022, 6, 3178-3188.	5.2	6
40	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 3615-3615.	1.4	5
41	Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. <i>Spanish MDS Group (GESMD)</i> . <i>Blood</i> , 2012, 120, 3803-3803.	1.4	3
42	Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array. <i>Leukemia Research</i> , 2011, 35, e161-e163.	0.8	2
43	Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2015, 56, 3183-3188.	1.3	2
44	Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 487-490.	0.2	1
45	(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1264-1266.	7.2	1
46	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	2.8	1
47	Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features. <i>Blood</i> , 2019, 134, 4266-4266.	1.4	1
48	LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients. <i>Blood</i> , 2010, 116, 5054-5054.	1.4	1
49	The Complete Mutatome and Clonal Architecture of Del(5q). <i>Blood</i> , 2015, 126, 608-608.	1.4	1
50	Clonal Dynamics of JAK2V617F and Non-Driver Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy. <i>Blood</i> , 2021, 138, 3623-3623.	1.4	1
51	Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. <i>Leukemia Research</i> , 2022, 112, 106771.	0.8	1
52	Reply to M.A. Lichtman. <i>Journal of Clinical Oncology</i> , 2017, 35, 1376-1377.	1.6	0
53	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. <i>Leukemia Research</i> , 2021, 101, 106492.	0.8	0
54	Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.. <i>Blood</i> , 2008, 112, 1649-1649.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V617F Status. Blood, 2008, 112, 2788-2788.	1.4	0
56	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	1.4	0
57	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	1.4	0
58	Multilineage Dysplasia Confers Poor Prognosis to Patients with De Novo Acute Myeloid Leukemia with Intermediate-Risk Cytogenetics and Wild-Type NPM1.. Blood, 2012, 120, 2551-2551.	1.4	0
59	Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. Blood, 2013, 122, 1551-1551.	1.4	0
60	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	1.4	0
61	Whole-Exome Sequencing in Myelodysplastic Syndromes with 5q Deletion. Blood, 2014, 124, 4635-4635.	1.4	0
62	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	1.4	0
63	Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1. Blood, 2014, 124, 1910-1910.	1.4	0
64	Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome. Blood, 2014, 124, 4649-4649.	1.4	0
65	Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts. Blood, 2015, 126, 2894-2894.	1.4	0
66	RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?. Blood, 2015, 126, 2866-2866.	1.4	0
67	Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category. Blood, 2016, 128, 3185-3185.	1.4	0
68	Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts. Blood, 2016, 128, 1991-1991.	1.4	0
69	Diagnostic Utility of Flow Cytometric Immunophenotyping in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 5526-5526.	1.4	0
70	Immunophenotypic Characteristics of Olygomonocytic Chronic Myelomonocytic Leukemia Support Its Diagnosis As a Distinctive Entity in the Continuum of Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 5520-5520.	1.4	0
71	Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation. Blood, 2019, 134, 2687-2687.	1.4	0
72	Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas. Blood, 2019, 134, 2899-2899.	1.4	0

#	ARTICLE	IF	CITATIONS
73	High Diagnostic Utility of Flow Cytometry Based Peripheral Blood Monocyte Subset Analysis, CD56 and CD2 Expression in Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 5437-5437.	1.4	0
74	Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment. Blood, 2019, 134, 4262-4262.	1.4	0
75	Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes. Blood, 2021, 138, 1530-1530.	1.4	0
76	Early Immune Profile Assessment By Flow Cytometry Predicts Severe COVID-19 Pneumonia. Blood, 2021, 138, 4197-4197.	1.4	0
77	Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 1533-1533.	1.4	0
78	Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes. Blood, 2021, 138, 2599-2599.	1.4	0
79	Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes. Leukemia and Lymphoma, 2021, , 1-9.	1.3	0